Guidance for market authorization requirements for COVID-19 drugs: Rolling submissions and reviews - Guidance for market authorization requirements for COVID-19 drugs: Rolling submissions and reviews
There are no views created for this resource yet.
Additional Information
Created | July 28, 2022 |
---|---|
Format | HTML |